NCT02672475: Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

NCT02672475
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known AR+ tumor. If the AR status is unknown, the patient can go on study; Patients with untreated or symptomatic metastatic central nervous system (CNS) disease- see trial for details
https://ClinicalTrials.gov/show/NCT02672475

Comments are closed.

Up ↑